889 related articles for article (PubMed ID: 27865762)
1. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
2. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
3. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
4. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
5. Imaging-assisted anticancer nanotherapy.
Dasgupta A; Biancacci I; Kiessling F; Lammers T
Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines for advanced cancer treatments: Transitioning towards responsive systems.
van Elk M; Murphy BP; Eufrásio-da-Silva T; O'Reilly DP; Vermonden T; Hennink WE; Duffy GP; Ruiz-Hernández E
Int J Pharm; 2016 Dec; 515(1-2):132-164. PubMed ID: 27725268
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
[TBL] [Abstract][Full Text] [Related]
10. Theranostic nanomedicine.
Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
[TBL] [Abstract][Full Text] [Related]
11. Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.
Durymanov MO; Rosenkranz AA; Sobolev AS
Theranostics; 2015; 5(9):1007-20. PubMed ID: 26155316
[TBL] [Abstract][Full Text] [Related]
12. Bioinspired approaches for cancer nanotheranostics.
Evangelopoulos M; Tasciotti E
Nanomedicine (Lond); 2017 Jan; 12(1):5-7. PubMed ID: 27876435
[No Abstract] [Full Text] [Related]
13. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
14. Biocompatible polymersomes-based cancer theranostics: Towards multifunctional nanomedicine.
Mohammadi M; Ramezani M; Abnous K; Alibolandi M
Int J Pharm; 2017 Mar; 519(1-2):287-303. PubMed ID: 28115259
[TBL] [Abstract][Full Text] [Related]
15. Ligand-targeted theranostic nanomedicines against cancer.
Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R
J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878
[TBL] [Abstract][Full Text] [Related]
16. Voyage of theranostic liposomes for imaging and therapy.
Sachin M; Sachin D; Dinesh S
J Cosmet Laser Ther; 2017 Aug; 19(4):245-249. PubMed ID: 28135901
[TBL] [Abstract][Full Text] [Related]
17. Theranostic application of nanoemulsions in chemotherapy.
Gorain B; Choudhury H; Nair AB; Dubey SK; Kesharwani P
Drug Discov Today; 2020 Jul; 25(7):1174-1188. PubMed ID: 32344042
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicines based drug delivery systems for anti-cancer targeting and treatment.
Jain V; Jain S; Mahajan SC
Curr Drug Deliv; 2015; 12(2):177-91. PubMed ID: 25146439
[TBL] [Abstract][Full Text] [Related]
19. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging.
Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO
Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951
[No Abstract] [Full Text] [Related]
20. Towards tailored management of malignant brain tumors with nanotheranostics.
Aparicio-Blanco J; Torres-Suárez AI
Acta Biomater; 2018 Jun; 73():52-63. PubMed ID: 29678675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
